Author Archives: admin


Israelis and Emiratis to develop COVID-19 stem-cell therapy – JNS.org

(August 19, 2020 / Israel21c) Fast on the heels of the agreement between Israel and the United Arab Emirates (UAE) to establish full diplomatic relations, Haifa-based Pluristem Therapeutics has signed a non-binding memorandum of understanding (MoU) with the Abu Dhabi Stem Cells Center to advance cell therapies for diseases including COVID-19.

The aim of the collaboration is to capitalize on each companys respective areas of expertise in cell therapies to deliver regenerative medicine for the benefit not only of the citizens of the UAE and Israel, but for humanity as a whole, Pluristem explained in a press release on Aug. 17.

Pluristem has treated patients with its placental PLX-PAD allogenic product via compassionate-use programs in Israel and the United States and is currently conducting phase II studies in the United States and European Union.

Abu Dhabi Stem Cells Center has been treating COVID-19 patients with stem cells sourced from the patients blood, by returning the cells back into the patients lungs as a fine mist through a nebulizer.

Subscribe to The JNS Daily Syndicate by email and never miss our top stories

The collaboration, initiated by the Better Alternatives advisory firm, would involve exchanging research results, patient samples and testing equipment.

I believe it is our obligation and privilege as business and scientific leaders to lead the way forward to strengthen collaborations and promote innovation and education. We are honored to be on the front line of this historical moment, said Pluristem CEO and President Yaky Yanay.

This is not the first COVID-related joint project between the two countries.

In July, Rafael Advanced Defense Systems and Israel Aerospace Industries signed agreements with Abu Dhabis Group 42 concerning R&D collaborations for solutions to SARS-CoV-2, the virus that causes COVID-19. On Aug. 15, UAEs APEX National Investment signed a strategic commercial agreement with Israels TeraGroup concerning SARS-CoV-2 research.

The Pluristem-Abu Dhabi Stem Cells Center MoU was signed in a video conference. But soon it may be possible to make a three-hour flight between the two Middle East countries. Israeli Prime Minister Benjamin Netanyahu said on Aug. 17 that Israel is working to enable flights between Israel and the United Arab Emirates to use Saudi airspace.

This article was first published by Israel21c.

Read the original:
Israelis and Emiratis to develop COVID-19 stem-cell therapy - JNS.org

Stem Cell Therapeutics Market | Industry Demand Status by Size, Progress Strategies, Manufacturers, Regions, Trends, Challenges, And Forecast by…

INC. and CAPRICOR THERAPEUTICS INC.

Market Dynamics :

>Drivers
>Restraints
>Opportunities
-

Based On Biological Analysis Stem Cell Therapeutics Market Report Covers Consumption Volume Analysis, Sales Volume, Performance and Share, Sales Price and Sales Revenue Analysis of Regions:

United States, Canada, Mexico, United Kingdom, France, Germany, Italy, Spain, Rest of Europe, India, China, Japan, Australia, South Korea, Rest of APAC, GCC, South Africa, Rest of MEA, Brazil,Argentina, Rest of South Africa

Key Developments in the Market:: > February 2018: Astellas Acquires Universal Cells, Inc. to create cell therapy products. > January 2018: Astellas Completes Acquisition of Mitobridge, Inc.

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/13102459

Important Questions Answered in the Report:

Highlighted points of Market Report:

Purchase this Report (Price 4250 USD for single-user license) https://www.industryresearch.co/purchase/13102459

Stem Cell Therapeutics Market Covers Following Points in TOC:

Chapter 1: Stem Cell Therapeutics Market Definition

Chapter 2: Research Methodology of Stem Cell Therapeutics Market

Chapter 3: Stem Cell Therapeutics Market Executive Summary

Chapter 4: Stem Cell Therapeutics Market Overview Includes Current Market Scenario, Porters Five Forces Analysis, Bargaining Power of Suppliers and Consumers, Threat of New Entrants and Substitute Product and Services

Chapter 5: Market Dynamics Covers Drivers, Restraints, Opportunities and Challenges

Chapter 6: Stem Cell Therapeutics Market Segmentation by Types, End-User, and Applications Forecast to 2023

Chapter 7: Stem Cell Therapeutics Market Segmentation by Geographical Regions

Chapter 8: Competitive Landscape of Stem Cell Therapeutics Market Includes Mergers & Acquisition Analysis, Agreements, Collaborations, and Partnerships, New Products Launches

Chapter 9: Key Players for Stem Cell Therapeutics Market

For Detailed TOC Click Here

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Healthcare Linen Market Size, Share and CAGR Status 2020 Global Industry Data by Top Manufacturers, Business Boosting Strategies, Upcoming Trends, Emerging Growth Factors till 2026

Ceramic Rod Market 2020 Global Industry Size Estimation, Research Update, Future Scope, Revenue, Pricing Trends, Growth Opportunity, Regional Outlook and Forecast to 2025

VoIP Software Market 2020 Industry Outlook by Business Share, Industry Price Trend, Size Estimation, Latest Research Report by Business Analysis and Forecast Research till 2025

Universal Power Line Carrier (UPLC) Market 2020: Global Industry Overview by Top Key Players Size, Share, Future Growth, Development, Revenue, and Growth Factors up to 2025

Dipentene (Limonene) Market 2020: Top Coverage of Key Companies with Size and Share, Expected Growth Analysis with Revenue, Future Trends and Technology Forecast by 2026

Autocrane Market Share 2020: Global Industry Outlook by Growth Segments, Types, Applications, and End-User Analysis Industry Size, Forecast to 2026

More:
Stem Cell Therapeutics Market | Industry Demand Status by Size, Progress Strategies, Manufacturers, Regions, Trends, Challenges, And Forecast by...

Facts & Factors Predicts that by 2026 the Size of the Biologics Safety Testing Market Grow at 11.5% – PharmiWeb.com

According to Facts and Factors,the globalbiologics safety testing marketin 2019 was approximately USD 3.3 Billion. The market is expected to grow above a CAGR of 11.5% and is anticipated to reach over USD 6.83 Billion by 2026.

Biologics products applied to products from biological sources that are produced. Biologics are used as medical items in animals and humans. Such biologics contain serum and blood products, large polypeptides, vaccines, antitoxins, toxins, viruses, etc. The protection of biologics is an important criterion for its use in animals and humans and also for regulatory approvals. The demand for the biologics safety testing market is driven by growing demand for biologics to address the burden of various chronic diseases, rising investment in life science research and development, rapid growth in new product launches, growth in pharmaceutical and biopharmaceutical research and increased prevalence of chronic disorders.

Request an Exclusive Free Sample PDF Report of Biologics Safety Testing Market @ https://www.fnfresearch.com/sample/biologics-safety-testing-market-by-product-services-instruments-946

(The sample of this report is readily available on request).

Benefits of Requesting a FREE PDF Sample Report Before Purchase:

(Note: The sample of this report is updated with COVID-19 impact analysis before delivery)

Spreadsheet Chapters include

Market Consumption in US$ by Country by Product/Service by Year. Market, Financial, Competitive, Market Segmentation, Industry, Critical Parameters, Marketing Costs, Markets, Decision Makers, Performance, Product Launch.

The global biologics safety testing market has been segmented on the basis of product, test type, and application. On the basis of product segment, the target market is segmented into reagents and kits, services, and instruments. Also, on the basis of test type segment the global market is segmented into endotoxin tests, sterility tests, cell line authentication and characterization tests, residual host contamination detection tests, adventitious agent detection tests, bioburden tests, and other tests. Application segment is bifurcated as vaccine and therapeutics development, blood and blood-related products testing, cellular and gene therapy, tissue and tissue-related products testing, and stem cell research.

Enquire more about this report before purchase @ https://www.fnfresearch.com/inquiry/biologics-safety-testing-market-by-product-services-instruments-946

(You may enquire a report quote OR available discount offers to our sales team before purchase.)

North America continues to dominate the global market for the target market, owing to the presence of key operating players in the target market. Also, the availability of advanced healthcare facilities in the countries if this region is also propelling growth of the target market in this region. Furthermore, growth in the focus on the new vaccine and therapeutics development by pharmaceutical and biopharmaceutical companies is expected to fuel market growth in the region. The Asia Pacific market is expected to rise at a faster rate of growth as a result of increased awareness among people, increased investment in R&D, the use of skilled labor to produce products and increased investment by the pharmaceutical industry. Also, the market in the Middle East and Africa is expected to show lucrative growth opportunities in the countries of this region.

Top key players operating in the market are Merck KGaA, Pace Analytical Services Inc., Charles River Laboratories, Toxikon Corporation, Cytovance Biologics, Inc., Sartorius AG, Thermo Fisher Scientific Inc., WuXi Apptec, SGS SA, Lonza Group LTD. and among others. The key players operating in the global biologics safety testing market are focusing on the organic as well as inorganic growth strategies to get a competitive edge in the global market. Innovations and the launch of advanced products are creating opportunities in the target market.

Request Customized Copy of Report @ https://www.fnfresearch.com/customization/biologics-safety-testing-market-by-product-services-instruments-946

(We customize your report according to your research need. Ask our sales team for report customization.)

This report segments the Biologics Safety Testing market as follows:

Global Biologics Safety TestingMarket: ByProduct

Global Biologics Safety TestingMarket:By Test Type

Global Biologics Safety TestingMarket:By Application

Global Biologics Safety Testing Market Market: Regional Segmentation Analysis

About Us:

Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our clients/customers conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.

See the original post here:
Facts & Factors Predicts that by 2026 the Size of the Biologics Safety Testing Market Grow at 11.5% - PharmiWeb.com

Animal Stem Cell Therapy Market: Rising Demand and Growth Opportunity – Owned

COVID-19 Outbreak-Global Animal Stem Cell Therapy Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020 is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changinginvestment structure of the COVID-19 Outbreak-Global Animal Stem Cell Therapy Market. Some of the key players profiled in the study are Aratana Therapeutics, Cell Therapy Sciences, VETSTEM BIOPHARMA, Magellan Stem Cells, U.S. Stem Cell, VetCell Therapeutics, J-ARM, Animal Care Stem, ANIMAL CELL THERAPIES, Cells Power Japan, MediVet Biologic, Animacel & Celavet.

COVID-19 Outbreak- Animal Stem Cell Therapy Market Overview:

If you are involved in the COVID-19 Outbreak- Animal Stem Cell Therapy industry or intend to be, then this study will provide you comprehensive outlook. Its vital you keep your market knowledge up to date segmented by Veterinary Hospitals & Research Organizations, , Dogs, Horses & Others and major players. If you want to classify different company according to your targeted objective or geography we can provide customization according to your requirement.

You can get free access to samples from the report here:https://www.htfmarketreport.com/sample-report/2781942-covid-19-outbreak-global-animal-stem-cell-therapy-industry-market

COVID-19 Outbreak- Animal Stem Cell Therapy Market: Demand Analysis & Opportunity Outlook 2025

COVID-19 Outbreak- Animal Stem Cell Therapy research study is to define market sizes of various segments & countries by past years and to forecast the values by next 5 years. The report is assembled to comprise each qualitative and quantitative elements of the industry facts including: market share, market size (value and volume 2014-19, and forecast to 2025) which admire each countries concerned in the competitive examination. Further, the study additionally caters the in-depth statistics about the crucial elements which includes drivers & restraining factors that defines future growth outlook of the market.

Important years considered in the study are: Historical year 2014-2019 ; Base year 2019; Forecast period** 2020 to 2025 [** unless otherwise stated]

The segments and sub-section of COVID-19 Outbreak- Animal Stem Cell Therapy market are shown below:

The Study is segmented by following Product Type: , Dogs, Horses & Others

Major applications/end-users industry are as follows: Veterinary Hospitals & Research Organizations

Some of the key players/Manufacturers involved in the Market are Aratana Therapeutics, Cell Therapy Sciences, VETSTEM BIOPHARMA, Magellan Stem Cells, U.S. Stem Cell, VetCell Therapeutics, J-ARM, Animal Care Stem, ANIMAL CELL THERAPIES, Cells Power Japan, MediVet Biologic, Animacel & Celavet

Enquire for customization in Report @https://www.htfmarketreport.com/enquiry-before-buy/2781942-covid-19-outbreak-global-animal-stem-cell-therapy-industry-market

If opting for the Global version of COVID-19 Outbreak- Animal Stem Cell Therapy Market analysis is provided for major regions as follows: North America (USA, Canada and Mexico) Europe (Germany, France, the United Kingdom, Netherlands, Russia , Italy and Rest of Europe) Asia-Pacific (China, Japan, Australia, New Zealand, South Korea, India and Southeast Asia) South America (Brazil, Argentina, Colombia, rest of countries etc.) Middle East and Africa (Saudi Arabia, United Arab Emirates, Israel, Egypt, Nigeria and South Africa)

Buy this research report @https://www.htfmarketreport.com/buy-now?format=1&report=2781942

Key Answers Captured in Study are Which geography would have better demand for product/services? What strategies of big players help them acquire share in regional market? Countries that may see the steep rise in CAGR & year-on-year (Y-O-Y) growth? How feasible is market for long term investment? What opportunity the country would offer for existing and new players in the COVID-19 Outbreak- Animal Stem Cell Therapy market? Risk side analysis involved with suppliers in specific geography? What influencing factors driving the demand of COVID-19 Outbreak- Animal Stem Cell Therapy near future? What is the impact analysis of various factors in the COVID-19 Outbreak-Global Animal Stem Cell Therapy market growth? What are the recent trends in the regional market and how successful they are?

Read Detailed Index of full Research Study at @https://www.htfmarketreport.com/reports/2781942-covid-19-outbreak-global-animal-stem-cell-therapy-industry-market

There are 15 Chapters to display the COVID-19 Outbreak-Global Animal Stem Cell Therapy market. Chapter 1, About Executive Summary to describe Definition, Specifications and Classification of COVID-19 Outbreak-Global Animal Stem Cell Therapy market, Applications [Veterinary Hospitals & Research Organizations], Market Segment by Types , Dogs, Horses & Others; Chapter 2, objective of the study. Chapter 3, to display Research methodology and techniques. Chapter 4 and 5, to show the COVID-19 Outbreak- Animal Stem Cell Therapy Market Analysis, segmentation analysis, characteristics; Chapter 6 and 7, to show Five forces (bargaining Power of buyers/suppliers), Threats to new entrants and market condition; Chapter 8 and 9, to show analysis by regional segmentation[North America (Covered in Chapter 7 and 14), United States, Canada, Mexico, Europe (Covered in Chapter 8 and 14), Germany, UK, France, Italy, Spain, Russia, Others, Asia-Pacific (Covered in Chapter 9 and 14), China, Japan, South Korea, Australia, India, Southeast Asia, Others, Middle East and Africa (Covered in Chapter 10 and 14), Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Others, South America (Covered in Chapter 11 and 14), Brazil, Argentina, Columbia, Chile & Others ], comparison, leading countries and opportunities; Regional Marketing Type Analysis, Supply Chain Analysis Chapter 10, to identify major decision framework accumulated through Industry experts and strategic decision makers; Chapter 11 and 12, COVID-19 Outbreak-Global Animal Stem Cell Therapy Market Trend Analysis, Drivers, Challenges by consumer behavior, Marketing Channels Chapter 13 and 14, about vendor landscape (classification and Market Ranking) Chapter 15, deals with COVID-19 Outbreak-Global Animal Stem Cell Therapy Market sales channel, distributors, Research Findings and Conclusion, appendix and data source.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia or Oceania [Australia and New Zealand].

About Author: HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.

Contact US : Craig Francis (PR & Marketing Manager) HTF Market Intelligence Consulting Private Limited Unit No. 429, Parsonage Road Edison, NJ New Jersey USA 08837 Phone: +1 (206) 317 1218 [emailprotected]

Connect with us atLinkedIn|Facebook|Twitter

Read more here:
Animal Stem Cell Therapy Market: Rising Demand and Growth Opportunity - Owned

Cell Viability Assays Market: Global Growth Analysis, Share, Demand by Regions, Types and Analysis of Top Key Players Research Forecasts to 2026 -…

A new market research study titledGlobal Cell Viability Assays Market 2019explores several significant factors of the market and evaluates the global market. The report includes breakdown data by manufacturers, key regions, types, and application, which presents a detailed analysis of the drivers and restraints impacting the overallGlobal Cell Viability Assays Market.

Global Cell Viability Assays MarketBy Products (Consumables, Instruments), Cell Type (Human Cells, Microbial Cells, Animal Cells), Applications (Stem Cell Research, Clinical & Diagnostics Applications, Drug Discovery & Development, Basic Research, Other Applications), End-Users (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Hospital & Diagnostics Laboratories, Other End-Users), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends & Forecast to 2026Global Cell Viability Assays Marketis expected to rise from its initial estimated value of USD 2.75 billion in 2018 to an estimated value of USD 5.30 billion by 2026, registering a CAGR of 8.57% in the forecast period of 2019-2026.

Cell Viability Assays Market report comprises of a chapter on the global market and all of its associated companies with their profiles, which gives important information and data pertaining to their outlook in terms of finances, product portfolios, investment plans, and marketing and business strategies. The report has information on product development, market sales, regional trade, investment calculation, investment opportunity, trade outlook, policy, regional market and another important characteristic of the Cell Viability Assays Market.

Get a Sample PDF of Global Cell Viability Assays Market Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cell-viability-assays-market

Few of the major competitors currently working in the cell viability assays market are Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, GENERAL ELECTRIC COMPANY, Danaher, BD, Promega Corporation, Biotium, Abcam plc, BioTek Instruments, Inc., PerkinElmer Inc., Pfizer Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc. and Gilead Sciences, Inc., Others.

Market Definition: Global Cell Viability Assays Market

Viability means ability to survive or live. Cell viability is a homogeneous method to determine the number of cells that are dead or living on a total cell sample. They are usually based on the ongoing cellular metabolism and enzyme activity. The increase in the cell viability means that there is cell growth while decrease in the cell viability means that toxic effects of compound. To determine the optimal growth conditions of the cell populations often call viability is very useful.

Market Drivers

Market Restraints

The report can answer the following questions:

Get Detailed TOC with Tables and Figures athttps://www.databridgemarketresearch.com/toc/?dbmr=global-cell-viability-assays-market

Segmentation: Global Cell Viability Assays Market

Key Developments in the Market:

Inquiry Before Buying @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cell-viability-assays-market

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

More:
Cell Viability Assays Market: Global Growth Analysis, Share, Demand by Regions, Types and Analysis of Top Key Players Research Forecasts to 2026 -...

At 8.4% CAGR, STEM CELL BANKING Market Size is Expected to Exhibit 11.2 Billion US$ by 2025 – Scientect

STEM CELL BANKINGMarket Size Covers Global Industry Analysis, Size, Share, CAGR, Trends, Forecast and Business Opportunity.

Download Premium Sample of the Report:https://brandessenceresearch.biz/Request/Sample?ResearchPostId=269&RequestType=Sample

Global STEM CELL BANKING Market to reach USD 11.2 billion by 2025.

Global STEM CELL BANKING Market valued approximately USD 5.4 billion in 2016 is anticipated to grow with a healthy growth rate of more than 8.4% over the forecast period 2017-2025. Global Rise in number of births and increase in R&D activities in regards with applications of stem cells, and surge in prevalence of fatal chronic diseases are owing towards a driving force for the growth of the market. The growth in GDP & disposable income is projected to help in increasing the number of stem cell units stored, which in turn boosts the market growth. The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Application oSample Collection & Transportation oSample Processing oSample Analysis oSample Preservation & Storage By Regions: oNorth America oU.S. oCanada oEurope oUK oGermany oAsia Pacific oChina oIndia oJapan oRest of the World

Furthermore, years considered for the study are as follows:

Historical year 2015 Base year 2016 Forecast period 2017 to 2025

Some of the key manufacturers involved in the market are. Cord Blood Registry, ViaCord, Cryo-Cell, China Cord Blood Corporation, Cryo-Save, New York Cord Blood Program, Cord Vida, Americold, CryoHoldco, and Vita34. Other prominent players in the value chain include Caladrius Biosciences, Cryoviva, Smart Cells International Ltd., Stemade Biotech, Cytori Therapeutics, Cellular Dynamics International, PerkinElmer, and Reelabs Acquisitions and effective mergers are some of the strategies adopted by the key manufacturers. New product launches and continuous technological innovations are the key strategies adopted by the major players.

Target Audience of the Global STEM CELL BANKING in Market Study:

oKey Consulting Companies & Advisors oLarge, medium-sized, and small enterprises oVenture capitalists oValue-Added Resellers (VARs) oThird-party knowledge providers oInvestment bankers oInvestors

Key factors influencing market growth:

Request Customization of the Report: https://brandessenceresearch.biz/Request/Sample?ResearchPostId=269&RequestType=Methodology

Customization of the Report:

Brandessence Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

To summarize, the STEM CELL BANKING market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Reports:

https://www.marketwatch.com/press-release/life-sciences-bpo-market-size-will-observe-substantial-growth-by-2025-2020-08-18

https://www.marketwatch.com/press-release/global-gene-expression-analysis-market-size-2020-newest-industry-data-future-trends-and-forecast-2025-2020-08-18

https://www.marketwatch.com/story/mouth-ulcers-drugs-market-size2020-growth-types-trends-size-share-and-top-key-players-by-forecast-research-2025-2020-08-18

https://www.marketwatch.com/press-release/laser-direct-imaging-ldi-system-market-size-2020-growing-demand-analysis-industry-growth-regional-revenue-top-company-profiles-cagr-values-2020-08-12?tesla=y

https://www.marketwatch.com/press-release/thermal-management-market-size-share-industry-analysis-and-top-companies-aavid-thermalloy-llc-honeywell-international-inc-european-thermodynamics-ltd-vertiv-co-advanced-cooling-technologies-inc-2020-08-14?tesla=y

Link:
At 8.4% CAGR, STEM CELL BANKING Market Size is Expected to Exhibit 11.2 Billion US$ by 2025 - Scientect

On the move at the OneAZ, Spencer Fane, UArizona – AZ Big Media

OneAZ Credit Union names Ken Bauer SVP

OneAZ Credit Union announced Ken Bauer as senior vice president, Credit Administration.

Bauer oversees OneAZs mortgage, business and commercial banking teams, emphasizing efficiency and excellence to help the organization succeed. He joined OneAZ Credit Union in 2020, bringing 20 years of experience in commercial banking with local and national banks and credit unions.

Established in 1951, OneAZ Credit Union is owned by its members and serves Arizona with 20 locations and more than 140,000 members

Spencer Fane LLP announced Kelly Mooney has joined the firm as of counsel. She will be part of the Tax, Trusts, & Estates practice group and work out of the firms Phoenix office.

Mooneys practice focuses on handling complex matters related to federal taxation, working with attorneys in other practice groups to structure transactions that comply with federal tax law, offer tax relief when applicable, and provide tax-efficient results for her clients. She regularly assists clients with tax planning and analysis for partnerships, LLCs, and corporations; real estate joint ventures organized as LLCs and general and limited partnerships; and individuals.

Spencer Fane understands that tax issues impact virtually every aspect of business, investment, and personal wealth management, said Andy Federhar, Spencer Fane office managing partner in Phoenix. We understand our clients needs to assist them with finding the best solutions to favorably handle their tax liability, and Kellys experience in handling these matters through collaborative analysis fits well with our firms approach to client service.

Mooney has an accomplished track record of representing clients before the Internal Revenue Service and other taxing authorities on ruling requests, civil controversy cases, and collection matters. Her work has included successfully negotiating the settlement of several complex and multiyear IRS examinations and cases involving the imposition of trust fund penalties and contested claims for refund.

The University of Arizona College of Nursing has announced key new appointments, promotions, honors, awards and other notable items in recent weeks, including:

After a national search, the UArizona College of Nursing has named Kelley Wilson, DNP, MSN, CMSRN, as the new program director of the colleges Master of Science for Entry to the Profession of Nursing (MEPN) program. Dr. Wilson joins the college from Georgetown Universitys School of Nursing and Health Studies, where she had been serving as program director for the schools Bachelor of Science in Nursing program. She assumed her new role on July 13.

Dr. Wilson brings a wealth of experience in teaching and developing courses and academic programs, said Connie Miller, DNP, RNC-OB, CNE, clinical associate professor and chair, General Nursing and Health Education Division. She has solid experience in mentoring and leading teams, in addition to proven track record of service and scholarship. We look forward to welcoming her to our MEPN team.

Aleeca Bell, PhD, RN, CNM, joined the College of Nursing in mid-July. Dr. Bell most recently was an associate professor at the University of Illinois at Chicago (UIC), College of Nursing, Department of Women Children and Family Health Science. At UIC, she also earned her masters degree in nursing in midwifery in 1998, practiced as a certified nurse midwife, and earned a doctorate in nursing in 2009. In addition, she was a postdoctoral fellow there from 2009-11.

Dr. Bells research in translational, multidisciplinary and biobehavioral clinical studies focuses on the intersection of perinatal mother-infant health outcomes and the underlying oxytocin system. Oxytocin is a hormone that acts on organs in womens bodies and as a chemical messenger in the brain, controlling key aspects of the reproductive system, including childbirth, lactation and some behavior. This includes womens childbirth experience, intrapartum medical interventions, the endogenous oxytocin system (hormonal, genetic and epigenetic), maternal postnatal mood/anxiety and caregiving attitudes, newborn behaviors and mother-infant interaction. Learn more.

Tracy E. Crane, PhD, a College of Nursing assistant professor, has focused much of her career on cancer survivorship. She is co-director of the Behavioral Measurements and Interventions Shared Resource at the UArizona Cancer Center and a member of the UArizona Data Science Institute. Shes also co-chair of the cancer prevention and control behavioral science working group for NRG Oncology, a research non-profit led by faculty at Columbia University, NYU Langone Health, the University of Michigan and UArizona.

With a research focus on improving adherence to healthy lifestyle behaviors in cancer survivors and their informal caregivers, Dr. Crane has developed interventions geared toward extending lifespans of post-treatment ovarian cancer survivors and telephone counseling to improve diet and physical activity in Latina cancer patients. In early 2020, Dr. Crane extended her expertise across the Atlantic when she helped researchers at Gustave Roussy, Europes largest cancer center, fine-tune a new cancer study, Motivating to Exercise and Diet, and Educating to Healthy Behaviors After Breast Cancer (MEDEA).

In keeping with Dr. Cranes previous research, MEDEA aims to compare the effect of a personalized telephone-based health education weight-loss program based on motivational coaching, exercise and diet, compared with a standard health educational program control on fatigue of overweight or obese breast cancer patients. Learn more.

According to new research from College of Nursing Associate Professor Ruth Taylor-Piliae, PhD, RN, FAHA, tai chi can be beneficial to the psychological well-being for adults suffering from cardiovascular disease. Published in June in the European Journal of Cardiovascular Nursing, Dr. Taylor-Piliaes review and meta-analysis of more than a dozen studies on the topic found that the exercise eased stress, anxiety, depression and psychological distress for those who practiced the mind-body exercise that emphasizes concentration on posture, relaxation and breathing, using a soothing series of set movements. Go to the UArizona Health Sciences Connect website for a video on her research. Learn more.

Three cardiologists recently joined the University of Arizona Sarver Heart Center. Arka Chatterjee, MD, Talal Moukabary, MD, and Madhan Sundaram, MBBS, joined the faculty of the UArizona College of Medicine Tucson and are now seeing patients at Banner University Medical Center Tucson.

With the addition of Drs. Chatterjee, Moukabary and Sundaram we continue the rapid growth in cardiovascular medicine at the University of Arizona and Banner UMC Tucson and we enhance our ability to provide highly personalized and expert care in the most advanced cardiology procedures to our patients, said Nancy K. Sweitzer, MD, PhD, director of the UArizona Sarver Heart Center, professor of medicine and chief of the Division of Cardiology in the Department of Medicine at the college.

These three physicians not only bring experience in electrophysiology, coronary and peripheral interventions and minimally invasive valve replacement, but they will expand the research offerings of the Sarver Heart Center in important areas of cardiology. This will allow us to bring the latest advances in heart disease treatment to the people of Southern Arizona, added Dr. Sweitzer.

Drs. Chatterjee and Moukabary are associate professors and Dr. Sundaram is an assistant professor of medicine.

In addition, Dr. Chatterjee is associate director of the Structural Heart Program at Banner UMC Tucson. He is board certified in interventional cardiology, cardiovascular disease, internal medicine and echocardiography. Dr. Chatterjee is experienced in transcatheter therapies for valvular disease and other congenital/structural heart defects. He has completed more than 200 transcatheter aortic valve replacement (TAVR) procedures. He finds the best part of working in the structural heart team is the synergy that occurs when a multidisciplinary team of expert providers works together to identify the ideal treatment for each patients unique case. Dr. Chatterjees research interests include outcomes research after coronary, structural and adult congenital interventions, and advances in structural and device therapies for heart disease.

Dr. Moukabary is a cardiac electrophysiologist (a cardiologist specializing in heart rhythm disorders or arrhythmias). He is an expert in computer modeling of cardiac arrhythmia, imaging in the cardiac electrophysiology lab, cell-based arrhythmia therapy and clinical cardiac electrophysiology. He is board certified in clinical cardiac electrophysiology and internal medicine. Dr. Moukabarys research interests include use of stem cell and iPS (induced pluripotent stem) cell therapies for heart rhythm disorders.

Dr. Sundaram is director of the Banner UMC Tucson Cardiac Catheterization Lab and Endovascular Services. He is board certified in interventional cardiology, cardiovascular disease, echocardiography and internal medicine. His clinical interests include complex coronary interventions, chronic total occlusions, endovascular peripheral interventions, interventions for acute pulmonary embolism and structural heart disease interventions. His research interests include cardiac interventions in older adults and clinical trials in coronary artery disease, peripheral artery disease and pulmonary embolism.

Continued here:
On the move at the OneAZ, Spencer Fane, UArizona - AZ Big Media

Induced Pluripotent Stem Cells Market Size Is Anticipated To Reach US$ 17200 Mn at a CAGR of 7% By 2026, Owing to Increasing Number of Product…

The healthcare industry has been focusing on excessive research and development in the last couple of decades to ensure that the need to address issues related to the availability of drugs and treatments for certain chronic diseases is effectively met. Healthcare researchers and scientists at the Li Ka Shing Faculty of Medicine of the Hong Kong University have successfully demonstrated the utilization of human induced pluripotent stem cells or hiPSCs from the skin cells of the patient for testing therapeutic drugs.

The success of this research suggests that scientists have crossed one more hurdle towards using stem cells in precision medicine for the treatment of patients suffering from sporadic hereditary diseases. iPSCs are the new generation approach towards the prevention and treatment of diseases that takes into account patients on an individual basis considering their genetic makeup, lifestyle, and environment. Along with the capacity to transform into different body cell types and same genetic composition of the donors, hiPSCs have surfaced as a promising cell source to screen and test drugs.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/17968

Company Profile

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/17968

In the present research, hiPSC was synthesized from patients suffering from a rare form of hereditary cardiomyopathy owing to the mutations in Lamin A/C related cardiomyopathy in their distinct families. The affected individuals suffer from sudden death, stroke, and heart failure at a very young age. As on date, there is no exact treatment available for this condition.

This team in Hong Kong tested a drug named PTC124 to suppress specific genetic mutations in other genetic diseases into the iPSC transformed heart muscle cells. While this technology is being considered as a breakthrough in clinical stem cell research, the team at Hong Kong University is collaborating with drug companies regarding its clinical application.

The unique properties of iPS cells provides extensive potential to several biopharmaceutical applications. iPSCs are also used in toxicology testing, high throughput, disease modeling, and target identification. This type of stem cell has the potential to transform drug discovery by offering physiologically relevant cells for tool discovery, compound identification, and target validation.

A new report by Persistence Market Research (PMR) states that the globalinduced pluripotent stem or iPS cell marketis expected to witness a strong CAGR of 7.0% from 2018 to 2026. In 2017, the market was worth US$ 1,254.0 Mn and is expected to reach US$ 2,299.5 Mn by the end of the forecast period in 2026.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/17968

Customization to be the Key Focus of Market Players

Due to the evolving needs of the research community, the demand for specialized cell lines have increased to a certain point where most vendors offering these products cannot depend solely on sales from catalog products. The quality of the products and lead time can determine the choices while requesting custom solutions at the same time. Companies usually focus on establishing a strong distribution network for enabling products to reach customers from the manufacturing units in a short time period.

Entry of Multiple Small Players to be Witnessed in the Coming Years

Several leading players have their presence in the global market; however, many specialized products and services are provided by small and regional vendors. By targeting their marketing strategies towards research institutes and small biotechnology companies, these new players have swiftly established their presence in the market.

Report Highlights:

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish Kolte Persistence Market Research Address 305 Broadway, 7th FloorNew York City, NY 10007 United States U.S. Ph. +1-646-568-7751 USA-Canada Toll-free +1 800-961-0353 Sales[emailprotected] Websitehttps://www.persistencemarketresearch.com

Go here to see the original:
Induced Pluripotent Stem Cells Market Size Is Anticipated To Reach US$ 17200 Mn at a CAGR of 7% By 2026, Owing to Increasing Number of Product...

First lab-made ‘mini-hearts’ mimic the real thing – Futurity: Research News

Share this Article

You are free to share this article under the Attribution 4.0 International license.

Researchers have created, for the first time, a miniature human heart model in the laboratory.

The mini-hearts are complete with all primary heart cell types and a functioning structure of chambers and vascular tissue.

The organoids are small models of the fetal heart with representative functional and structural features. They are, however, not as perfect as a human heart yet. That is something we are working toward.

These mini-hearts constitute incredibly powerful models in which to study all kinds of cardiac disorders with a degree of precision unseen before, says Aitor Aguirre, assistant professor of biomedical engineering at Michigan State Universitys Institute for Quantitative Health Science and Engineering and senior author of the study on the work on the bioRxiv preprint server. In the United States, heart disease is the leading cause of death.

The researchers created the human heart organoids, or hHOs for short,by way of a novel stem cell framework that mimics the embryonic and fetal developmental environments.

Organoidsmeaning resembling an organare self-assembling 3D cell constructs that recapitulate organ properties and structure to a significant extent, says first author Yonatan Israeli, a graduate student in Aguirres lab.

The innovation deploys a bioengineering process that uses induced pluripotent stem cellsadult cells from a patient to trigger embryonic-like heart development in a dishgenerating a functional mini-heart after a few weeks. The stem cells are obtained from consenting adults and therefore free of ethical concerns.

This process allows the stem cells to develop, basically as they would in an embryo, into the various cell types and structures present in the heart, Aguirre says. We give the cells the instructions and they know what they have to do when all the appropriate conditions are met.

Because the organoids followed the natural cardiac embryonic development process, the researchers studied, in real time, the natural growth of an actual fetal human heart.

This technology allows for the creation of numerous hHOs simultaneously with relative ease, contrasting with existing tissue engineering approaches that are expensive, labor intensive and not readily scalable.

One of the primary issues facing the study of fetal heart development and congenital heart defects is access to a developing heart. Researchers have been confined to the use of mammalian models, donated fetal remains, and in vitro cell research to approximate function and development.

Now we can have the best of both worlds, a precise human model to study these diseasesa tiny human heartwithout using fetal material or violating ethical principles. This constitutes a great step forward, Aguirre says.

Whats next? For Aguirre, the process is twofold. First, the heart organoid represents an unprecedented look into the nuts and bolts of how a fetal heart develops.

In the lab, we are currently using heart organoids to model congenital heart diseasethe most common birth defect in humans affecting nearly 1% of the newborn population, Aguirre says. With our heart organoids, we can study the origin of congenital heart disease and find ways to stop it.

And second, while the hHO is complex, it is far from perfect. For the team, improving the final organoid is another key avenue of future research.

The organoids are small models of the fetal heart with representative functional and structural features, Israeli says. They are, however, not as perfect as a human heart yet. That is something we are working toward.

The researchers are excited about the wide-ranging applicability of these miniature hearts. They enable an unprecedented ability to study many other cardiovascular-related diseasesincluding chemotherapy-induced cardiotoxicity and the effect of diabetes, during pregnancy, on the developing fetal heart.

Additional researchers from Michigan State and Washington University in St. Louis contributed to the work.

The American Heart Association and the National Institutes of Health funded the study.

Source: Michigan State University

Original Study DOI: 10.1101/2020.06.25.171611

See original here:
First lab-made 'mini-hearts' mimic the real thing - Futurity: Research News

Scientists grow the first functioning mini human heart model – MSUToday

Michigan State University researchers have created for the first time a miniature human heart model in the laboratory, complete with all primary heart cell types and a functioning structure of chambers and vascular tissue.

Aitor Aguirre, assistant professor of biomedical engineering at MSUs Institute for Quantitative Health Science and Engineering.

These minihearts constitute incredibly powerful models in which to study all kinds of cardiac disorders with a degree of precision unseen before, said Aitor Aguirre, the studys senior author and assistant professor of biomedical engineering at MSUs Institute for Quantitative Health Science and Engineering.

This study, Generation of Heart Organoids Modeling Early Human Cardiac Development Under Defined Conditions, appears on the bioRxiv preprint server and was funded by grants from the American Heart Association and the National Institutes of Health. In the United States, heart disease is the No. 1 cause of death.

The human heart organoids, or hHOs for short, were created by way of a novel stem cell framework that mimics the embryonic and fetal developmental environments.

Organoids meaning resembling an organ are self-assembling 3D cell constructs that recapitulate organ properties and structure to a significant extent, said Yonatan Israeli, a graduate student in the Aguirre Lab and first author of the study.

The innovation deploys a bioengineering process that uses induced pluripotent stem cells adult cells from a patient to trigger embryonic-like heart development in a dish generating a functional mini heart after a few weeks. The stem cells are obtained from consenting adults and therefore free of ethical concerns.

This process allows the stem cells to develop, basically as they would in an embryo, into the various cell types and structures present in the heart, Aguirre said. We give the cells the instructions and they know what they have to do when all the appropriate conditions are met.

Because the organoids followed the natural cardiac embryonic development process, the researchers studied, in real time, the natural growth of an actual fetal human heart.

This technology allows for the creation of numerous hHOs simultaneously with relative ease, contrasting with existing tissue engineering approaches that are expensive, labor intensive and not readily scalable.

One of the primary issues facing the study of fetal heart development and congenital heart defects is access to a developing heart. Researchers have been confined to the use of mammalian models, donated fetal remains and in vitro cell research to approximate function and development.

Now we can have the best of both worlds, a precise human model to study these diseases a tiny human heart without using fetal material or violating ethical principles. This constitutes a great step forward, Aguirre said.

Whats next? For Aguirre, the process is twofold. First, the heart organoid represents an unprecedented look into the nuts and bolts of how a fetal heart develops.

In the lab, we are currently using heart organoids to model congenital heart disease the most common birth defect in humans affecting nearly 1% of the newborn population, Aguirre said. With our heart organoids, we can study the origin of congenital heart disease and find ways to stop it.

And second, while the hHO is complex, it is far from perfect. For the team, improving the final organoid is another key avenue of future research. The organoids are small models of the fetal heart with representative functional and structural features, Israeli said. They are, however, not as perfect as a human heart yet. That is something we are working toward.

Aguirre and team are excited about the wide-ranging applicability of these miniature hearts. They enable an unprecedented ability to study many other cardiovascular-related diseases from chemotherapy-induced cardiotoxicity to the effect of diabetes, during pregnancy, on the developing fetal heart.

Other researchers involved in this study were Aaron Wasserman, Mitchell Gabalski and Kristen Ball at MSU; and Chao Zhou, Jinyon Zhou and Guangming Ni at Washington University in St. Louis.

(Note for media: Please include a link to the original paper in online coverage: https://www.biorxiv.org/content/10.1101/2020.06.25.171611v2)

Link:
Scientists grow the first functioning mini human heart model - MSUToday